Mayo Clinic Alix School of Medicine, Mayo Clinic.
Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic Medical Scientist Training Program.
J Glaucoma. 2021 Jun 1;30(6):508-514. doi: 10.1097/IJG.0000000000001827.
In this longitudinal study of patients with open-angle (OAG), pseudoexfoliative (PXE), or neovascular glaucoma (NVG) receiving glaucoma drainage devices (GDD), posttube cumulative rates of reoperation, corneal graft, and visually threatening complications (VT-complications) increased beyond 5 years and were not significantly affected by glaucoma type.
To study the need for additional glaucoma surgery and development of complications after first GDD surgery in eyes with primary OAG, PXE, or NVG glaucoma.
There were 306 eyes with OAG (n=185), PXE (n=60), or NVG (n=61) glaucoma who received a first GDD between 1996 and 2017. Outcomes including glaucoma reoperation, corneal graft procedure, and VT-complications after GDD were measured. Kaplan-Meier analysis was used to compare cumulative rate of reaching outcomes over time after GDD placement among the 3 glaucoma groups.
When comparing the OAG, PXE, and NVG groups, there were no significant differences in post-GDD cumulative rates of reoperation (P=0.33), corneal graft (P=0.26), or VT-complications (P=0.65) over time. For all eyes, the overall cumulative rates for each outcome measure increased beyond 5 years, and specific Kaplan-Meier rates (5-y, 10-y) included: reoperation (16%, 25%), corneal graft (6%, 12%), VT-complications (9%, 14%). When comparing specific GDDs, the Ahmed FP7 had a higher cumulative reoperation rate over time compared with the Baerveldt 350 (P=0.019).
Glaucoma type did not significantly affect post-GDD cumulative rates of reoperation, corneal graft, and VT-complication among the OAG, PXE, and NVG groups. For all eyes, cumulative rates of reoperation, corneal graft, and VT-complications increased beyond 5 years. The Ahmed FP7 had a significantly higher cumulative reoperation rate compared with the Baerveldt 350 over time.
在这项针对接受青光眼引流装置 (GDD) 的开角型 (OAG)、假性剥脱性 (PXE) 或新生血管性青光眼 (NVG) 患者的纵向研究中，术后累计再手术、角膜移植和威胁视力的并发症 (VT-并发症) 的发生率在 5 年后仍持续增加，且不受青光眼类型的显著影响。
研究原发性 OAG、PXE 或 NVG 青光眼患者首次 GDD 手术后是否需要进一步的青光眼手术以及并发症的发展。
共有 306 只眼患有 OAG（n=185）、PXE（n=60）或 NVG（n=61）青光眼，于 1996 年至 2017 年间接受了首次 GDD 治疗。测量 GDD 后青光眼再手术、角膜移植手术和 VT-并发症的发生情况。Kaplan-Meier 分析用于比较 GDD 放置后 3 种青光眼组中达到结局的累积率随时间的变化。
比较 OAG、PXE 和 NVG 组，GDD 后再手术（P=0.33）、角膜移植（P=0.26）或 VT-并发症（P=0.65）的累积率无显著差异。对于所有眼，每种结局指标的总体累积率在 5 年后均增加，具体的 Kaplan-Meier 率（5 年、10 年）包括：再手术（16%、25%）、角膜移植（6%、12%）、VT-并发症（9%、14%）。比较特定的 GDD，Ahmed FP7 随着时间的推移，其累计再手术率明显高于 Baerveldt 350（P=0.019）。
青光眼类型对 OAG、PXE 和 NVG 组 GDD 术后再手术、角膜移植和 VT-并发症的累积率无显著影响。对于所有眼，再手术、角膜移植和 VT-并发症的累积率在 5 年后均增加。Ahmed FP7 随着时间的推移，其累计再手术率明显高于 Baerveldt 350。
